Read by QxMD icon Read

“Mathew williams”

James Richard Alexander Smith, John Abraham Mathews, Lindsay Osborne, Zoe Bakewell, James Leigh Williams
AIMS: Despite kneeling being an important and valued function of the knee, a proportion of patients are unable to kneel following arthroplasty. We explore the reasons for this, and assess whether neuropathic pain is a contributing factor. METHODS: In this observational study, data was collected prospectively for 134 knees. At one year follow-up, patients completed a semi-structured questionnaire, the Oxford Knee Score (OKS), and the painDETECT score. Ability to kneel was assessed by question 7 of the OKS...
February 13, 2019: Knee
Helen M McRae, Alexandra L Garnham, Yifang Hu, Matthew T Witkowski, Mark A Corbett, Mathew P Dixon, Rose E May, Bilal N Sheikh, William Chiang, Andrew J Kueh, Tan A Nguyen, Kevin Man, Renee Gloury, Brandon J Aubrey, Antonia Policheni, Ladina Di Rago, Warren S Alexander, Daniel H D Gray, Andreas Strasser, Edwin D Hawkins, Stephen Wilcox, Jozef Gécz, Axel Kallies, Matthew P McCormack, Gordon K Smyth, Anne K Voss, Tim Thomas
Somatically acquired mutations in PHF6 ( plant homeodomain finger 6 ) frequently occur in hematopoietic malignancies and often coincide with ectopic expression of TLX3 However, there is yet no functional evidence to demonstrate whether these mutations contribute to tumorigenesis. Similarly, the role of PHF6 in hematopoiesis is unknown. We report here that Phf6 deletion in mice resulted in a reduced number of hematopoietic stem cells, an increased number of hematopoietic progenitor cells, and an increased proportion of cycling stem and progenitor cells...
February 12, 2019: Blood
James H Hull, Emil S Walsted, Christopher M Orton, Parris Williams, Simon Ward, Mathew J Pavitt
Exercise-induced laryngeal obstruction (EILO) is a prevalent problem causing exertional breathlessness and wheeze. This report demonstrates the feasibility and safety of a diagnostic approach to EILO, using a portable laryngoscope during exercise.
February 2019: ERJ Open Research
Zhiping Li, Xuanmao Jiao, Gabriele Di Sante, Adam Ertel, Mathew C Casimiro, Min Wang, Sanjay Katiyar, Xiaoming Ju, D V Klopfenstein, Aydin Tozeren, William Dampier, Iouri Chepelev, Albert Jeltsch, Richard G Pestell
Lysine methylation of histones and non-histone substrates by the SET domain containing protein lysine methyltransferase (KMT) G9a/EHMT2 governs transcription contributing to apoptosis, aberrant cell growth, and pluripotency. The positioning of chromosomes within the nuclear three-dimensional space involves interactions between nuclear lamina (NL) and the lamina-associated domains (LAD). Contact of individual LADs with the NL are dependent upon H3K9me2 introduced by G9a. The mechanisms governing the recruitment of G9a to distinct subcellular sites, into chromatin or to LAD, is not known...
February 4, 2019: Oncogene
Binita Shah, Pedro A Villablanca, Sreekanth Vemulapalli, Pratik Manandhar, Nicholas S Amoroso, Muhamed Saric, Cezar Staniloae, Mathew R Williams
BACKGROUND: Renal disease is associated with poor prognosis despite guideline-directed cardiovascular therapy, and outcomes by sex in this population remain uncertain. METHODS AND RESULTS: Patients (n=5213) who underwent a MitraClip procedure in the National Cardiovascular Data Registry Transcatheter Valve Therapy registry were evaluated for the primary composite outcome of all-cause mortality, stroke, and new requirement for dialysis by creatinine clearance (CrCl)...
February 2019: Circulation. Cardiovascular Interventions
Keri N Althoff, Kelly A Gebo, Richard D Moore, Cynthia M Boyd, Amy C Justice, Cherise Wong, Gregory M Lucas, Marina B Klein, Mari M Kitahata, Heidi Crane, Michael J Silverberg, M John Gill, William Christopher Mathews, Robert Dubrow, Michael A Horberg, Charles S Rabkin, Daniel B Klein, Vincent Lo Re, Timothy R Sterling, Fidel A Desir, Kenneth Lichtenstein, James Willig, Anita R Rachlis, Gregory D Kirk, Kathryn Anastos, Frank J Palella, Jennifer E Thorne, Joseph Eron, Lisa P Jacobson, Sonia Napravnik, Chad Achenbach, Angel M Mayor, Pragna Patel, Kate Buchacz, Yuezhou Jing, Stephen J Gange
BACKGROUND: Adults with HIV have an increased burden of non-AIDS-defining cancers, myocardial infarction, end-stage liver disease, and end-stage renal disease. The objective of this study was to estimate the population attributable fractions (PAFs) of preventable or modifiable HIV-related and traditional risk factors for non-AIDS-defining cancers, myocardial infarction, end-stage liver disease, and end-stage renal disease outcomes. METHODS: We included participants receiving care in academic and community-based outpatient HIV clinical cohorts in the USA and Canada from Jan 1, 2000, to Dec 31, 2014, who contributed to the North American AIDS Cohort Collaboration on Research and Design and who had validated non-AIDS-defining cancers, myocardial infarction, end-stage liver disease, or end-stage renal disease outcomes...
February 2019: Lancet HIV
Maria G Otero, Emmanuelle Tiongson, Frank Diaz, Katrina Haude, Karin Panzer, Ashley Collier, Jaemin Kim, David Adams, Cynthia J Tifft, Hong Cui, Francisca Millian Zamora, Margaret G Au, John M Graham, David J Buckley, Richard Lewis, Camilo Toro, Renkui Bai, Lesley Turner, Katherine D Mathews, William Gahl, Tyler Mark Pierson
COX20/FAM36A encodes a mitochondrial complex IV assembly factor important for COX2 activation. Only one homozygous COX20 missense mutation has been previously described in two separate consanguineous families. We report four subjects with features that include childhood hypotonia, areflexia, ataxia, dysarthria, dystonia, and sensory neuropathy. Exome sequencing in all four subjects identified the same novel COX20 variants. One variant affected the splice donor site of intron-one (c.41A>G), while the other variant (c...
January 2019: Annals of Clinical and Translational Neurology
Daniel Radwan, Edward Cachay, Oluwaseun Falade-Nwulia, Richard D Moore, Ryan Westergaard, William Christopher Mathews, Judith Aberg, Laura Cheever, Kelly A Gebo
BACKGROUND: Despite the high prevalence of Hepatitis C Virus (HCV) among persons living with HIV (PWH), the prevalence of HCV screening, treatment, and sustained virologic response (SVR) is unknown. This study aims to characterize the continuum of HCV screening and treatment among PWH in HIV care. SETTING: Adult patients enrolled at 12 sites of the HIV Research Network located in three regions of the United States were included. METHODS: We examined the prevalence of HCV screening, HCV coinfection, direct-acting antiretroviral (DAA) treatment, and SVR-12 between 2014-15...
January 8, 2019: Journal of Acquired Immune Deficiency Syndromes: JAIDS
Alan F Vainrib, Didier F Loulmet, Mathew R Williams, Muhamed Saric
No abstract text is available yet for this article.
December 2019: Circulation. Cardiovascular Imaging
Andrew G Horti, Ravi Naik, Catherine A Foss, Il Minn, Varia Misheneva, Yong Du, Yuchuan Wang, William B Mathews, Yunkou Wu, Andrew Hall, Catherine LaCourse, Hye-Hyun Ahn, Hwanhee Nam, Wojciech G Lesniak, Heather Valentine, Olga Pletnikova, Juan C Troncoso, Matthew D Smith, Peter A Calabresi, Alena V Savonenko, Robert F Dannals, Mikhail V Pletnikov, Martin G Pomper
While neuroinflammation is an evolving concept and the cells involved and their functions are being defined, microglia are understood to be a key cellular mediator of brain injury and repair. The ability to measure microglial activity specifically and noninvasively would be a boon to the study of neuroinflammation, which is involved in a wide variety of neuropsychiatric disorders including traumatic brain injury, demyelinating disease, Alzheimer's disease (AD), and Parkinson's disease, among others. We have developed [11 C]CPPC [5-cyano- N -(4-(4-[11 C]methylpiperazin-1-yl)-2-(piperidin-1-yl)phenyl)furan-2-carboxamide], a positron-emitting, high-affinity ligand that is specific for the macrophage colony-stimulating factor 1 receptor (CSF1R), the expression of which is essentially restricted to microglia within brain...
January 11, 2019: Proceedings of the National Academy of Sciences of the United States of America
Tim J Sloan, James C Turton, Jess Tyson, Alison Musgrove, Vicki M Fleming, Michelle M Lister, Matthew W Loose, R Elizabeth Sockett, Mathew Diggle, Frances L Game, William Jeffcoate
PURPOSE: While some micro-organisms, such as Staphylococcus aureus, are clearly implicated in causing tissue damage in diabetic foot ulcers (DFUs), our knowledge of the contribution of the entire microbiome to clinical outcomes is limited. We profiled the microbiome of a longitudinal sample series of 28 people with diabetes and DFUs of the heel in an attempt to better characterize the relationship between healing, infection and the microbiome. METHODOLOGY: In total, 237 samples were analysed from 28 DFUs, collected at fortnightly intervals for 6 months or until healing...
January 9, 2019: Journal of Medical Microbiology
Robert J Fortuna, Thomas A Rocco, Jeffrey Freeman, Mathew Devine, John Bisognano, Geoffrey C Williams, Angela Nagel, Howard Beckman
Initiatives to improve hypertension control within academic medical centers and closed health systems have been extensively studied, but large community-wide quality improvement (QI) initiatives have been both less common and less successful in the United States. The authors examined a community-wide QI initiative across 226 843 patients from 198 practices in nine counties across upstate New York to improve hypertension control and reduce disparities. The QI initiative focused on (a) providing population and practice-level comparative data, (b) community engagement, especially in underserved communities, and (c) practice-level quality improvement assistance, but was not designed to examine causality of specific components...
January 4, 2019: Journal of Clinical Hypertension
Luke Law, Christine L Hunt, Andre J van Wijnen, Ahmad Nassr, A Noelle Larson, Jason S Eldrige, William D Mauck, Mathew J Pingree, Juan Yang, Casey W Muir, Patricia J Erwin, Mohamad Bydon, Wenchun Qu
Background: The use of mesenchymal stem cells (MSCs) in clinical applications for the treatment of musculoskeletal disease is steadily increasing in office-based practice. The so-called "first generation" of MSCs is defined as autologous stem cells that have undergone minimal manipulation and are used for a homologous purpose. Systematic reviews of the clinical trials completed to date of such MSCs enable practitioners to better understand what is currently known about the outcomes and side effects of such treatments...
December 29, 2018: Pain Medicine: the Official Journal of the American Academy of Pain Medicine
Andrew D Krystal, Diego A Pizzagalli, Sanjay J Mathew, Gerard Sanacora, Richard Keefe, Allen Song, Joseph Calabrese, Andrew Goddard, Wayne Goodman, Sarah H Lisanby, Moria Smoski, Richard Weiner, Dan Iosifescu, John Nurnberger, Steven Szabo, James Murrough, Anantha Shekhar, William Potter
No abstract text is available yet for this article.
December 28, 2018: Nature Reviews. Drug Discovery
Tetsuo Ashizawa, Cynthia Gagnon, William J Groh, Laurie Gutmann, Nicholas E Johnson, Giovanni Meola, Richard Moxley, Shree Pandya, Mark T Rogers, Ericka Simpson, Nathalie Angeard, Guillaume Bassez, Kiera N Berggren, Deepak Bhakta, Marco Bozzali, Ann Broderick, Janice L B Byrne, Craig Campbell, Edith Cup, John W Day, Elisa De Mattia, Denis Duboc, Tina Duong, Katy Eichinger, Anne-Berit Ekstrom, Baziel van Engelen, Belen Esparis, Bruno Eymard, Marla Ferschl, Shahinaz M Gadalla, Benjamin Gallais, Todd Goodglick, Chad Heatwole, James Hilbert, Venessa Holland, Marie Kierkegaard, Wilma J Koopman, Kari Lane, Daphne Maas, Ami Mankodi, Katherine D Mathews, Darren G Monckton, David Moser, Saman Nazarian, Linda Nguyen, Peg Nopoulos, Richard Petty, Janel Phetteplace, Jack Puymirat, Subha Raman, Louis Richer, Elisabetta Roma, Jacinda Sampson, Valeria Sansone, Benedikt Schoser, Laurie Sterling, Jeffrey Statland, S H Subramony, Cuixia Tian, Careniña Trujillo, Gordon Tomaselli, Chris Turner, Shannon Venance, Aparajitha Verma, Molly White, Stefan Winblad
Purpose of review: Myotonic dystrophy type 1 (DM1) is a severe, progressive genetic disease that affects between 1 in 3,000 and 8,000 individuals globally. No evidence-based guideline exists to inform the care of these patients, and most do not have access to multidisciplinary care centers staffed by experienced professionals, creating a clinical care deficit. Recent findings: The Myotonic Dystrophy Foundation (MDF) recruited 66 international clinicians experienced in DM1 patient care to develop consensus-based care recommendations...
December 2018: Neurology. Clinical Practice
Jennifer M Coughlin, Ting Yang, Alison W Rebman, Kathleen T Bechtold, Yong Du, William B Mathews, Wojciech G Lesniak, Erica A Mihm, Sarah M Frey, Erica S Marshall, Hailey B Rosenthal, Tristan A Reekie, Michael Kassiou, Robert F Dannals, Mark J Soloski, John N Aucott, Martin G Pomper
The pathophysiology of post-treatment Lyme disease syndrome (PTLDS) may be linked to overactive immunity including aberrant activity of the brain's resident immune cells, microglia. Here we used [11 C]DPA-713 and positron emission tomography to quantify the 18 kDa translocator protein, a marker of activated microglia or reactive astrocytes, in the brains of patients with post-treatment Lyme disease symptoms of any duration compared to healthy controls. Genotyping for the TSPO rs6971 polymorphism was completed, and individuals with the rare, low affinity binding genotype were excluded...
December 19, 2018: Journal of Neuroinflammation
Robert William O'Hara, Peter J Jenks, Matthew Emery, Mathew Upton
PURPOSE: Members of the ST127 uropathogenic E. coli (UPEC) clone have a high virulence potential and are also highly virulent in insect infection models. However, strains of this lineage are reported in relatively low numbers in many studies. ST127 strains are also usually widely susceptible to antibiotics and, consequently, their true prevalence may be under-recognized as they will be eradicated during empirical therapy. A genuine concern is the possibility that members of this highly virulent lineage will acquire resistance, leading to a more serious threat...
December 18, 2018: Journal of Medical Microbiology
Vinodh N Rajapakse, Augustin Luna, Mihoko Yamade, Lisa Loman, Sudhir Varma, Margot Sunshine, Francesco Iorio, Fabricio G Sousa, Fathi Elloumi, Mirit I Aladjem, Anish Thomas, Chris Sander, Kurt W Kohn, Cyril H Benes, Mathew Garnett, William C Reinhold, Yves Pommier
CellMinerCDB provides a web-based resource ( for integrating multiple forms of pharmacological and genomic analyses, and unifying the richest cancer cell line datasets (the NCI-60, NCI-SCLC, Sanger/MGH GDSC, and Broad CCLE/CTRP). CellMinerCDB enables data queries for genomics and gene regulatory network analyses, and exploration of pharmacogenomic determinants and drug signatures. It leverages overlaps of cell lines and drugs across databases to examine reproducibility and expand pathway analyses...
November 30, 2018: iScience
Patricia A Jorquera, Cynthia Mathew, Jennifer Pickens, Colin Williams, Jasmina M Luczo, Sharon Tamir, Reena Ghildyal, Ralph A Tripp
Respiratory syncytial virus (RSV) is a leading cause of hospitalization of infants and young children causing considerable respiratory disease and repeat infections that may lead to chronic respiratory conditions such as asthma, wheezing, and bronchitis. RSV causes ∼34 million new episodes of lower respiratory tract illness (LTRI) in children younger than 5 years of age with >3 million hospitalizations due to severe RSV-associated LRTI. The standard of care is limited to symptomatic relief as there are no approved vaccines and few effective antiviral drugs, thus a safe and efficacious RSV therapeutic is needed...
December 12, 2018: Journal of Virology
Jan A Burger, Mariela Sivina, Nitin Jain, Ekaterina Kim, Tapan Kadia, Zeev Estrov, Graciela M Nogueras-Gonzalez, Xuelin Huang, Jeffrey Jorgensen, Jianling Li, Mei Cheng, Fong Clow, Maro Ohanian, Michael Andreeff, Thomas Mathew, Philip Thompson, Hagop Kantarjian, Susan O'Brien, William G Wierda, Alessandra Ferrajoli, Michael J Keating
Ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase (BTK), is an effective therapy for CLL patients. To determine whether rituximab provides added benefit to ibrutinib, we conducted a randomized single center trial of ibrutinib versus ibrutinib plus rituximab. Patients with CLL requiring therapy were randomized to receive 28 day cycles of once-daily ibrutinib 420 mg, either as single agent (n=104), or together with rituximab (375 MG/m2 , n=104), given weekly during cycle 1, then once per cycle until cycle 6...
December 7, 2018: Blood
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"